首页> 美国卫生研究院文献>Journal of Cellular and Molecular Medicine >Development of a risk scoring system for patients with papillary thyroid cancer
【2h】

Development of a risk scoring system for patients with papillary thyroid cancer

机译:甲状腺乳头状癌患者风险评分系统的开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As the importance of personalized therapeutics in aggressive papillary thyroid cancer (PTC) increases, accurate risk stratification is required. To develop a novel prognostic scoring system for patients with PTC (n = 455), we used mRNA expression and clinical data from The Cancer Genome Atlas. We performed variable selection using Network‐Regularized high‐dimensional Cox‐regression with gene network from pathway databases. The risk score was calculated using a linear combination of regression coefficients and mRNA expressions. The risk score and clinical variables were assessed by several survival analyses. The risk score showed high discriminatory power for the prediction of event‐free survival as well as the presence of metastasis. In multivariate analysis, the risk score and presence of metastasis were significant risk factors among the clinical variables that were examined together. In the current study, we developed a risk scoring system that will help to identify suitable therapeutic options for PTC.
机译:随着个性化疗法在侵袭性甲状腺乳头状癌(PTC)中的重要性不断提高,需要准确的风险分层。为了开发针对PTC(n = 455)患者的新型预后评分系统,我们使用了The Cancer Genome Atlas的mRNA表达和临床数据。我们使用通路数据库中基因网络的网络正则化高维Cox回归进行变量选择。使用回归系数和mRNA表达的线性组合计算风险评分。通过几项生存分析评估风险评分和临床变量。风险评分对无事件生存以及转移的预测具有很高的区分力。在多变量分析中,风险得分和转移的存在是一起检查的临床变量中的重要风险因素。在当前的研究中,我们开发了一种风险评分系统,该系统将有助于为PTC确定合适的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号